Jagsonpal reports Q3 & 9MFY26 results with revenue steady and PAT up 12.5% YoY in Q3; nine-month revenue up 6% and PAT up 13%, cash balance at ₹1,757 mn. ESOP costs disclosed; management cites brand strength and disciplined operations.
AI Assistant
Jagsonpal Pharmaceuticals Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.